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ABSTRACT 
An observational study of INR control according to NICE criteria in patients 
with non-valvular atrial fibrillation-  
The SAIL Warfarin Out of Range Descriptors Study (SWORDS) 
Aims 
In patients with non-valvular atrial fibrillation (NVAF) prescribed warfarin, the UK 
National Institute of Health and Care Excellence (NICE) defines poor anticoagulation 
as a TTR of <65%, any 2 INRs within a 6 month period of ≤1.5 (“low”), 2 INRs ≥5 within 
6months, or any INR ≥ 8 (“high”). 
Our objectives were to (i) quantify the number of patients with poor INR control 
and (ii) describe the demographic and clinical characteristics associated with poor INR 
control. 
Method and results 
Linked anonymised health record data for Wales (2006-2017) was used to evaluate 
patients prescribed warfarin who had at least 6 months of INR data.  
32,380 patients were included. In total, 13,913 (43.0%) patients had at least 
one of the NICE markers of poor INR control. Importantly, in the 24,123 (74.6%) of the 
cohort with an acceptable TTR (≥65%), 5,676 (23.5%) had either low or high INR 
readings at some point in their history. In a multivariable regression female gender, 
age (≥75), excess alcohol, diabetes heart failure, ischaemic heart disease and 
respiratory disease were independently associated with all markers of poor INR 
control. 
 
Conclusion 
Acceptable INR control according to NICE standards is poor. Of those with an 
acceptable TTR (>65%) one quarter still had unacceptably low or high INR levels 
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according to NICE criteria. Thus, only using TTR to assess effectiveness with warfarin 
has the potential to miss a large number of patients with non-therapeutic INRs who 
are likely to be at increased risk. 
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MANUSCRIPT 
An observational study of INR control according to NICE criteria in patients 
with non-valvular atrial fibrillation. 
The SAIL Warfarin Out of Range Descriptors Study (SWORDS) 
INTRODUCTION 
 
Warfarin is the most common oral anticoagulant prescribed to reduce the risk of stroke 
in patients with atrial fibrillation (AF). Warfarin, like other Vitamin K antagonists (VKAs), 
has several limitations, including many drug-drug and drug-food interactions.1 
Furthermore, patient characteristics and comorbidities can lead to high intra-and inter-
patient variability in response.2, 3 In patients with non-valvular AF (NVAF) without any 
other indication for anticoagulation, current guidelines recommend an International 
Normalised Ratio (INR) range of 2.0 – 3.0.4-6 The net clinical benefit of warfarin is 
associated with the proportion of time that INR values are maintained within the 
therapeutic range, referred to as the time in therapeutic range (TTR).7, 8 
Subtherapeutic INR results are associated with an increase in thromboembolism9, 
while supertherapeutic INR results are associated with increased risk of bleeding 
including haemorrhagic stroke. 10-12 
In the UK, the National Institute for Health and Care Excellence (NICE) 
recommends that, in patients prescribed warfarin for AF to, “Reassess anticoagulation 
for a person with poor anticoagulation control shown by any of the following: two INR 
values higher than 5 or one INR value higher than 8 within the past 6 months; two INR 
values less than 1.5 within the past 6 months; [and/or] TTR less than 65%.”13 NICE 
advises that “If anticoagulation control cannot be improved, then the risks and benefits 
of alternative stroke prevention strategies should be discussed with the patient.” For 
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patients with non-valvular atrial fibrillation (NVAF) alternative anticoagulation with 
direct oral anticoagulants (DOACs) can now be provided. 14, 15 
  A number of observational studies and clinical trials have reported the TTR of 
patients prescribed VKAs for AF, 3, 10, 16-21 with the average TTR in these studies 
ranging from 53.7-68.4%, highlighting the increased risk of stroke and systemic 
embolism with subtherapeutic INR, as well as the excess bleeding risk with 
supertherapeutic INRs. However, the wider variability in INR control described by 
frequency of very low or very high INRs (as defined by NICE), as distinct from TTR, 
has not been previously described. This is of particular importance as it would 
characterise important therapeutic gaps at both an individual and population level, 
which are not captured by TTR alone.  
The objectives of this study were (i) to quantify the number of patients with 
NVAF prescribed warfarin who exhibit NICE-defined poor INR control and (ii) describe 
the demographic and clinical characteristics of these patients, as well as the 
relationship between these characteristics and poor INR control. 
METHOD 
Study design and data sources  
A retrospective observational cohort study was conducted using linked anonymised 
healthcare data for patients prescribed warfarin for NVAF between January 2006 and 
April 2017 in Wales, United Kingdom, using the Secure Anonymised Information 
Linkage (SAIL) Databank.22-24 SAIL is part of the national e-health records research 
infrastructure. The following datasets held within SAIL were linked: the Patient 
Episode Database for Wales (PEDW),25 which records hospital admission and 
discharge dates, diagnoses and operational procedures, demographic data, and date 
of death where applicable for the population of Wales; the Welsh Longitudinal General 
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Practice (WLGP) dataset26 containing demographic, clinical and prescribing data for 
approximately 76% of primary care practices across Wales; the Welsh Demographic 
(WDS) dataset,27 which contains basic demographic information and history of 
individuals’ residence in Wales and registration with GP practices; and the Welsh 
Index of Multiple Deprivation (WIMD) 2011,28 an area-based deprivation measure.   
Study subjects included those who had a diagnosis of AF/atrial flutter recorded 
in the WLGP dataset at any point prior to or during the study period and who were at 
least 18 years old at time of diagnosis. Patients were excluded if they had valvular AF 
(defined as AF in the presence of mitral stenosis, rheumatic mitral valve disease, prior 
mitral valve surgery and any metallic prosthetic heart valve), were pregnant during the 
study period, or had a history of Deep Vein Thrombosis (DVT) or Pulmonary Embolism 
(PE). This AF cohort was then restricted to patients who were prescribed warfarin 
during the study period and had at least 6 months of recurrent INR tests recorded in 
the WLGP dataset during the study period (excluding the first 6 weeks after start of 
treatment; a period when the warfarin dose is typically still being tailored to the 
patient’s needs).  
Medical history, demographic information and prescriptions 
A census date was assigned to each patient from when they met all of the inclusion 
criteria.  Demographic data, prior diagnoses, and comorbidities (chosen to reflect 
standard stroke and bleeding risk classification, and comorbidities of major organ 
systems) prior to the census date for each patient were identified. Individual age was 
calculated at the census date. The presence of heart failure, hypertension, vascular 
disease (defined as prior myocardial infarction (MI) or peripheral vascular disease 
(PVD) including peripheral artery disease and aortic plaque), prior stroke (including 
TIA), gender and age were used to calculate the individual CHA2DS2-VASc score. In 
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addition, the presence of the following were also identified prior to the census date for 
each patient (see supplementary table 1 for list codes): chronic kidney disease (CKD) 
stage 4+, chronic liver disease (including cirrhosis, fibrosis, chronic hepatitis and 
chronic active hepatitis, fatty liver, sclerosis of the liver, unspecified alcoholic liver 
damage, hepatic failure), dementia, thyroid disease (both hyper and hypothyroidism), 
epilepsy and respiratory disease, ischaemic heart disease (including stable, unstable 
and MI), haemorrhagic stroke, major bleeding events (including respiratory bleeds, 
urinary tract bleeds, intracranial bleeds and gastrointestinal bleeds) and excess 
alcohol consumption  
Calculation of individual Time in Therapeutic Range (TTR) and identification of 
low and high INRs 
NICE recommends using the Rosendaal method for calculating TTR; this method 
assumes a linear change in INR between consecutive tests (for example, if two 
consecutive INR tests are 2.5 and 3.5 with 30 days between tests, the method 
estimates that 15 days were in range, and 15 days were out of range.29 Thus, the 
estimated TTR is 50% during that 30 days period). 
 In this study, a modified Rosendaal method was used to calculate individual 
TTR. Following the census date for each patient, the first 6 weeks of INR results were 
excluded, to account for any initiation period. Individual INR results were identified, as 
well as the time span between them; when the interval between INR results was 
greater than 84 days, the INR test results were excluded from the overall calculation 
of individual TTR. The calculation began again when there were two INR results within 
84 days carried out because long gaps between INR tests most likely represented 
periods where treatment was discontinued. An INR value of less than 2.0 was 
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considered subtherapeutic and an INR value greater than 3.0 was considered 
supertherapeutic.  
Patients were categorised as having: (i) “unacceptable” or “acceptable” 
individual TTR control (< 65% or  65% respectively); (ii) “low” INRs (two INR results 
<1.5 in any 6-month period), or (iii) “high” INRs defined by two INR results greater than 
5 in any 6 month period or one result greater than 8. In addition, these three markers 
were combined into an overall “poor” INR control category, which included all patients 
with at least one of these NICE-defined indicators of poor control. Patients without any 
NICE criteria of poor INR control were categorised as “adequate” INR control. 
Statistical methods 
Baseline variables and characteristics of patients included in the analysis were 
presented as percentages or means with standard deviations. Characteristics of 
patients with each of the three markers of poor control, as well as the overall poor 
control category, were compared to those with “acceptable” INR control (defined as 
the absence of any marker of poor control). Differences in these characteristics 
between groups were summarised using chi-squared tests for categorical variables 
and independent t-tests for continuous variables. Next, we investigated two sets of 
multivariable models for the adverse outcomes. First, a binary logistic regression 
model was constructed with CHA2DS2-VASc score and deprivation index (using WIMD 
quintiles) as the predictors, and “poor” control vs “adequate” as the primary (binary) 
dependent outcome. This model was repeated with “unacceptable” TTR, “low” INR, 
and “high” INR as the dependent outcome (in each case in a binary comparison with 
“adequate” INR control).  
The second set of models attempted to identify all independent risk factors, by 
testing all available predictors from the baseline co-morbidities and risk factors 
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(including those components within the CHA2DS2-VASc score), age, gender and 
WIMD quintile. Binary dependent variables were the same as above (each of the three 
individual markers of poor control, as well as the overall poor control category, in 
comparison with a baseline good control). For this exploratory analysis, a large 
number of independent variables were considered, and the final set of predictors was 
chosen based on a search of all models (without interactions) and minimising the 
Bayesian Information Criterion (BIC).30 Model selection was also carried out using the 
lasso regularisation method,31 to check for consistency in the variables found in the 
final models. Analysis was carried out using SPSS version 22.0 and the package 
glmnet in R.32  
Missing data 
Comparisons were made between those included in the final cohort for analysis and 
(i) those with NVAF prescribed warfarin but with less than 6 months of INR test 
results for analysis, and (ii) those where there was no INR recorded in the WLGP 
dataset (see supplementary table 2). Finally, within the final cohort for analysis, 
comparisons were made between those with and without deprivation index data 
available (see supplementary table 3). 
RESULTS 
Over 4 million patient records were identified in the SAIL Databank during the study 
period; 110,592 had a diagnosis of AF and were aged over 18 at the time of diagnosis, 
of whom a total of 32,380 met the final inclusion criteria for this study (figure1). During 
a mean follow-up time of 4.3 years per patient, the mean TTR was 72.6%; 42.5% of 
the cohort was female; the mean age was 73.5 years (standard deviation = 9.7 years); 
and the median CHA2DS2-VASc score was 3 (table 1).  
 11 
 
Figure 1. Inclusion criteria for study cohort. 
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Table 1. Cohort demographics and medical history. N = 32,380 
 N (%) 
Age <65 5,412 (16.7) 
    65-74 10,875 (33.6) 
    >=75 16,093 (49.7) 
Female 13,751 (42.5) 
Deprivation index (quintile)  
   1 (most deprived) 5,309 (17.5) 
   2 5,875 (19.3) 
   3 6,728 (22.1) 
   4 5,862 (19.3) 
   5  6,645 (21.8) 
CHA2DS2-Vasc score  
   0 and 1 4,356 (13.5) 
   2 5,949 (18.4) 
   3 7,242 (22.4) 
   4 6,814 (21.0) 
   5 4,281 (13.2) 
   6 2,495 ( 7.7) 
   >=7 1,243 ( 3.8) 
Excessive alcohol intake 850 ( 2.6) 
Cancer 6,134 (18.9) 
CKD stage 4+ 375 ( 1.2) 
Dementia 364 ( 1.1) 
Diabetes 6,876 (21.2) 
Epilepsy 206 ( 0.6) 
Haemorrhagic stroke 204 ( 0.6) 
Heart failure 7,264 (22.4) 
Hypertension 21,234 (65.6) 
Ischaemic heart disease 9,641 (29.8) 
Ischaemic stroke 6,661 (20.6) 
Liver disease 611 ( 1.9) 
Major bleeding event 4,536 (14.0) 
Peripheral vascular disease 1,883 ( 5.8) 
Respiratory disease 6,305 (19.5) 
Thromboembolism 426 ( 1.3) 
Thyroid disease 4079 (12.6) 
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In total, 13,913 (43.0%) patients had at least one of the NICE markers of poor 
INR control (figure 2). Of this group, 8,237 (25.4%) had an unacceptable TTR (<65%) 
and 9,781 (30.2%) had two low INR readings within a six-month period. Overall, 3,148 
(9.7%) had high INRs during the study period, including 2,649 (8.2%) that had two or 
more INR results greater than 5 in a 6-month period, and 961 (3.0%) had an INR of 
greater than 8.  
In the 24,143 (74.6%) cohort with an acceptable TTR (≥65%), many had other 
signs of poor INR control: 5,090 (21.1%) had low INRs and 1,217 (5.0%) had high 
INRs. Overall, of those with acceptable TTR, 5,676 (23.5%) had either low or high INR 
readings at some point in their history. 
When considering European Society of Cardiology guidelines, which 
recommend a TTR ≥70%; 11, 876 (36.7%) of patients’ TTR fell below this threshold.6 
Furthermore, of the 20,504 patients with recommended TTR ≥70%, 3,990 (19.5%) 
patients met the NICE criteria for low or high INRs (supplementary figure 2). 
 
 
 14 
 
Figure 2. Number of patients with poor INR control according to NICE criteria.  
 
Patient characteristics associated with one or more signs of poor INR control include 
female sex, increasing social deprivation, increasing CHA2DS2-VASc score, heart 
failure, prior bleeding events, cancer, ischaemic heart disease, PVD, ischaemic 
stroke, thromboembolism, thyroid disease, respiratory disease, diabetes, epilepsy, 
dementia, excessive alcohol intake, liver disease, and CKD stage 4+(figure 3). 
Increasing CHA2DS2-VASc score from 2 was associated with an increasing likelihood 
of each marker of poor INR control, including the overall combined marker of poor INR 
control (figure 4). 
 15 
 
Figure 3. Characteristics associated with poor INR control. 
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Figure 4.  INR control verses thromboembolic risk 
 
Multivariable modelling 
In the first set of models, a CHA2DS2-VASc score of 3 or more was significantly 
associated with all markers of poor INR control (table 2). A similar relationship was 
observed between higher levels of deprivation and the risk of poor INR control.  
In the second set of models, exploring all possible independent variables, after BIC 
model selection, age, female gender, excess alcohol consumption, heart failure, 
ischaemic heart disease, respiratory disease and diabetes were independently 
associated with all measures of poor INR control (table 3). Peripheral vascular disease 
was associated with ‘poor control’, ‘high INRs’ and ‘TTR < 65%’ while prior major 
bleeding and dementia were associated with ‘poor control’ and ‘TTR < 65%’. 
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Ischaemic stroke was only associated with ‘high INRs’ and deprivation index was only 
associated with ‘TTR < 65%’. Highest adjusted odds ratios, across all markers or poor 
control, were detected for excess alcohol consumption, which is also predictive of 
bleeding. 
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Table 2. Multivariable logistic regression model of INR control verses deprivation index* and 
CHA2DS2-VASc score 
Predictor Poor Control Low INRs High INRs TTR <65% 
Deprivation index* (quintiles). Adjusted odds ratio (95% CI) 
  5 (Least 
deprived) 
Reference, 
overall p value 
<0.001 
 
Reference, 
overall p value 
<0.001 
 
Reference, 
overall p value 
<0.001 
 
Reference, 
overall p value 
<0.001 
  4 1.02 (0.95-1.10) 
 
0.99 (0.92-1.08) 1.05 (0.93-1.20) 1.07 (0.98-1.17) 
  3 1.12 (1.05-1.21) 
 
1.11 (1.02-1.19) 1.18 (1.05-1.33) 1.21 (1.12-1.32) 
  2 1.17 (1.09-1.26) 
 
1.12 (1.03-1.21) 1.31 (1.16-1.48) 1.32 (1.22-1.44) 
  1 (most 
deprived) 
1.21 (1.13-1.31) 
 
 
1.18 (1.09-1.28) 1.36 (1.20-1.54) 1.41 (1.30-1.54) 
CHA2DS2-VASc Score. Adjusted odds ratio (95% CI) 
0 or 1 Reference, 
overall p value 
<0.001 
 
Reference, 
overall p value 
<0.001 
 
Reference, 
overall p value 
<0.001 
 
Reference, 
overall p value 
<0.001 
 
2 0.94 (0.86-1.02) 
 
0.90 (0.82-0.98) 1.02 (0.87-1.19) 0.91 (0.82-1.01) 
3 1.13 (1.05-1.23) 
 
1.11 (1.01-1.21) 1.39 (1.19-1.61) 1.14 (1.04-1.26) 
4 1.27 (1.17-1.37) 
 
1.20 (1.10-1.32) 1.72 (1.49-2.01) 1.36 (1.23-1.50) 
5 1.53 (1.39-1.67) 
 
1.39 (1.26-1.53) 2.21 (1.85-2.65) 1.76 (1.58-1.95) 
6 1.62 (1.46-1.79) 
 
1.46 (1.30-1.63) 2.22 (1.90-2.59) 1.99 (1.77-2.25) 
≥7 1.82 (1.60-2.07) 
 
1.69 (1.46-1.96) 2.57 (2.07-3.20) 2.37 (2.04-2.75) 
*Deprivation index used is the WIMD quintile.28 
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Table 3. Multivariable regression models of patient characteristics verses INR control.a 
 
 Poor Control 
Adjusted odds 
ratio, (95% CI), 
p 
Low INRs 
Adjusted odds 
ratio, (95% CI), p 
High INRs 
Adjusted odds 
ratio, (95% CI), p 
TTR <65% 
Adjusted odds 
ratio, (95% CI), p 
Age ≤64 Reference, 
<0.001 
Reference, 
<0.001 
Reference, 
<0.001 
Reference, 
<0.001 
   65-74 0.84 (0.78-0.90) 0.82 (0.76-0.88) 0.88 (0.78-1.01) 0.76 (0.70-0.84) 
   ≥75 1.07 (1.00-1.15) 0.99 (0.92-1.06) 1.19 (1.06-1.35) 1.19 (1.09-1.28) 
Female 1.23 (1.17-1.29), 
<0.001 
1.25 (1.19-1.32), 
<0.001 
1.45 (1.33-1.57), 
<0.001 
1.29 (1.21-1.36), 
<0.001 
Excess alcohol 1.79 (1.55-2.08), 
<0.001 
1.62 (1.38-1.90), 
<0.001 
2.45 (1.97-3.03), 
<0.001 
2.32 (1.97-2.72), 
0.001 
Major bleeding 
events 
1.15 (1.08-1.23), 
0.001 
  1.23 (1.14-1.32), 
<0.001 
Cancer     
CKD stage 4+     
Dementia 1.51 (1.22-1.89), 
0.001 
  1.83 (1.44-2.33), 
<0.001 
     
Diabetes 1.20 (1.14-1.28), 
<0.001 
1.24 (1.17-1.32), 
<0.001 
1.21 (1.10-1.33), 
<0.001 
1.29 (1.21-1.38), 
0.001 
Epilepsy 
 
    
     
Heart failure 1.24 (1.17-1.31), 
<0.001 
1.17 (1.11-1.25), 
<0.001 
1.39 (1.27-1.53), 
<0.001 
1.42 (1.33-1.52), 
<0.001 
Hypertension  
 
   
Ischaemic heart 
disease 
1.17 (1.11-1.23), 
<0.001 
1.20 (1.14-1.27), 
<0.001 
1.22 (1.11-1.32), 
<.001 
1.20 (1.13-1.27), 
<.001 
Ischaemic stroke 
 
  1.24 (1.13-1.36), 
0.001 
 
Liver disease     
PVD 1.25 (1.13-1.38), 
<0.001 
 1.42 (1.22-1.65), 
<0.001 
1.35 (1.20-1.51), 
<0.001 
     
Respiratory 
disease 
1.51 (1.43-1.60), 
<0.001 
1.54 (1.45-1.64), 
<0.001 
1.75 (1.59-1.92), 
<0.001 
1.69 (1.59-1.82), 
<0.001 
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Thromboembolism 
 
Thyroid disease 
    
     
Deprivation indexb  
(quintiles) 
 
    
  5 (Least 
deprived) 
   Reference, 
<0.001 
  4    1.03 (0.95-1.13) 
  3    1.15 (1.06-1.26)  
  2    1.23 (1.13-1.35) 
  1 (most 
deprived) 
   1.28 (1.17-1.40) 
a All patient characteristics shown in table 1 were modelled, only characteristics that were 
significant in any of models are shown in the table.  
b Deprivation index used is the WIMD quintile.28 
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We found very good match between the variables selected by the BIC and Lasso 
model selection procedures (classifying by inclusion/exclusion the match was 78.9% 
for ‘poor control’, 89.4% for ‘Low’, 89.4% for ‘High’, 89.4% for ‘TTR < 65%’; see 
supplementary table 4). All predictors highlighted above were consistently selected by 
both procedures. BIC selection tended to be more conservative, with slightly fewer 
variables selected in the final models. 
DISCUSSION 
 
This is the first population study examining the effectiveness of warfarin therapy 
according to the NICE clinical guideline criteria for INR indicators of poor 
anticoagulation control, across a population with NVAF. In this study, only 57.0% of 
patients had adequate INR control according to NICE criteria. Increasing stroke risk, 
as assessed by the CHA2DS2-VASc score, was associated with a greater risk of poor 
INR control, as were many individual clinical characteristics that are also associated 
with increased risk of stroke or bleeding.  Unlike previous studies, not only was TTR 
evaluated but also the NICE criteria for unacceptably low and high INR levels. 
Importantly, we found that almost a quarter of those patients with acceptable TTR 
(>65%) demonstrated evidence of unacceptably low or high INR levels according to 
NICE criteria during the study period. These findings suggest that the risk of stroke, 
systemic embolism and/or bleeding, at both an individual patient and a population 
level, may be under-appreciated if TTR is followed as the sole measure of 
effectiveness of anticoagulation. Whilst it is important to recognize that the specific 
relationships between NICE low and high criteria and risks of major bleeding and 
stroke have not been definitively characterized, these are pragmatic values identifying 
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very low and high INR readings in chronically treated patients, defined by an expert 
consensus panel that should mandate clinical attention in UK practice.  
 This study evaluated the impact of multiple clinical and demographic factors in 
one of the largest real-world studies of INR control in patients with NVAF. Increasing 
CHA2DS2-VASc score (above 3), and hence increasing stroke risk, was strongly 
associated with poor INR control. As these patients are at the greatest thromboembolic 
risk and therefore likely to derive the greatest absolute benefits from effective 
anticoagulation, our data emphasise the particular importance of close monitoring and 
appropriate treatment selection in these vulnerable individuals. Individual risk factors 
for stroke including diabetes, heart failure, PVD, ischaemic heart disease and female 
gender were independently associated with markers of poor INR control. Prior major 
bleeding events and excess alcohol consumption, both risk factors for bleeding, were 
also associated with poor INR control. This is likely to reflect that patients with 
increasing comorbidity have an increasing number of potential influences on warfarin 
bioavailability and coagulation factor synthesis. 
 Previous studies have demonstrated that increasing CHA2DS2-VASc score, as 
well as comorbidities including heart failure, diabetes, CKD, chronic obstructive 
pulmonary disease, female sex, and lower income, are associated with lower TTR. 2, 
3, 21. The models presented in our study confirm this finding, and also show that both 
CHA2DS2-VASc score and multiple individual comorbidities are associated with low 
and high INRs. It is not known whether it is the direct physiological effect of these 
comorbidities, or medications prescribed for them, that are responsible for poor INR 
control; however, the observed association between increasing stroke risk and risk 
factors for bleeding associated with poor INR control warrants increased vigilance in 
those patients with increasing risk of stroke or bleeding. 
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The mean TTR of our cohort was higher than recorded in many previous 
studies, and the number of patients achieving adequate TTR had improved each year 
during the study (supplementary figure 1). Previous studies have suggested that INR 
management within anticoagulation clinics is associated with better TTR control.3, 33 
This study does not make comparisons between individual anticoagulation services or 
models of service delivery. There are several ways of delivering anticoagulation 
services in Wales, with many anticoagulation services being provided within primary 
care GP services. This may have contributed to the high TTR observed in this study, 
because it is also possible that patients who are difficult to control are managed within 
specialist anticoagulation services within secondary care, and their data were not 
included in this study. Furthermore, those with troublesome INR control may have 
been switched to direct oral anticoagulants (DOACs), a newer class of medications 
that were introduced in the latter period of this study. 
The observation that the number of patients with adequate TTR increased 
across the study period, yet the number with low or high INRs remained relatively 
constant, is of interest but unexplained.  It may be possible to improve TTR across the 
population through improved monitoring, interventions or patient selection, but less 
easy to prevent low or high INRs in response to acute events or changes to 
medication, especially in patients with multiple comorbidities that impact on INR 
variability.34-36 
We excluded AF patients with “valvular AF” (mitral stenosis, rheumatic mitral 
valve disease, prior mitral valve surgery or any metallic prosthetic heart valve), those 
with a history of DVT or PE and those pregnant during the study period. These patients 
may have had “individualised” INR targets, which would not necessarily have been 
identifiable in the SAIL databank and may potentially have biased the study towards a 
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greater number of patients with ‘poor INR control’ when applying specific NICE and/or 
ESC criteria for AF. Thus, we decided to take a conservative approach by excluding 
them from the analyses.  Furthermore, our clinical experience suggests that these 
more complex patients are more often managed via specialist secondary care 
haematology led anticoagulation services and their INR results would not have been 
available for analysis in this study. 
 
Strengths and limitations of this study 
This is the first study that has investigated not just TTR, but also low and high INR 
events, as markers of poor therapeutic control with warfarin therapy, allowing us to 
highlight that there is a substantial cohort of patients likely to be at risk of poor 
outcomes who may be missed if TTR is the sole focus.  
The use of a large, data-rich, linked population data source is a particular 
strength of this study. The linked primary and secondary care data held by SAIL enable 
the investigation of a very large cohort of individuals longitudinally over a period of 
years and across multiple data sources, giving a much more complete picture of 
patient treatment, health, and characteristics than previous studies. 
In calculating the TTR, NICE guidance recommends excluding the first six 
weeks of INR results and calculating the TTR over a maintenance period of six 
months. This recommendation was incorporated in to the methodology of this study.  
During the study period it is possible that there were temporary discontinuations of 
warfarin therapy due to acute illness, in response to elevated INR results or 
admissions to hospital. In order to address this, periods where there was a gap of 
greater than 84 days between INR readings were excluded, but this is an imperfect 
measure, and it is not possible to definitively identify gaps in treatment.  
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Although it may be argued that periods of temporary discontinuation should be 
excluded from assessing INR control according to NICE criteria, unless patients 
receive alternative treatment to reduce the risk of stroke, they are exposed to an 
increased risk of thromboembolic events. The destabilisation of INR control during 
acute illnesses and the prolonged subtherapeutic or supertherapeutic coagulation 
during gaps in anticoagulation is a recognised limitation in the use of warfarin. 
In total there were 17,905 patients identified with NVAF and prescribed warfarin 
that were excluded from the study, of which 5,368 did not have any INR readings 
available, and a further 10,190 that had insufficient INR readings (less than 6 months) 
to analyse. It is not known why 5,368 patients did not have INR readings recorded but 
it is possible that these patients were managed via coagulation clinics outside of the 
primary care setting and their results are not incorporated into the WLGP dataset.  It 
is not known what effect the incorporation of their results into this study would have 
made; however, these patients had a significantly higher rate of nearly all 
comorbidities and higher prevalence of excess alcohol consumption that were 
associated with greater likelihood of poor INR control in the models presented in this 
study.   
In the final cohort 1,959 (6.1%) had a missing deprivation index and were 
therefore excluded from the multivariable analyses.  This group had slightly lower 
prevalence of comorbidities (other than excess alcohol consumption), suggesting an 
overall lower risk group than those included in the multivariable analyses.  Regardless, 
all major comorbidities were well represented in the multivariable models and the 
inclusion of this group would not be expected to have a significant impact on the 
observed associations. 
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 Some patients may have had different, individualized INR targets, which would 
not be evaluable in this study. By identifying and excluding patients with valvular AF 
and those with other indications for anticoagulation, both groups with potentially higher 
INR targets, we have limited overestimates of poor INR control. The linkage of hospital 
and GP datasets has further improved the identification and exclusion of patients. 
However, it remains possible that undocumented valvular disease, multiple DVTs or 
PEs, or individually adjusted INR targets, may have resulted in the inclusion of patients 
with a targeted INR range outside of 2 to 3, who would then potentially be misclassified 
as having poor INR control. 
Due to the nature of the study, it was not possible to detect whether excess 
alcohol consumption has an interacting effect on warfarin, directly affected the INR, or 
was a marker of poor compliance. 
CONCLUSION 
 
In this study, forty three percent of Welsh patients had at least one marker of poor INR 
control. Of those with an acceptable TTR (>65%) one quarter still had unacceptably 
low or high INR levels according to NICE criteria. Paradoxically, patients at the highest 
risk of stroke and with risk factors for bleeding were most likely to have poor INR 
control and may benefit from closer attention to therapeutic effectiveness and 
alternative anticoagulation strategies where appropriate. If TTR is used as the sole 
measure of warfarin’s therapeutic effectiveness, the risk of stroke, systemic embolism 
and bleeding may well be under-estimated. Further work is required to define the 
specific level of risk associated with NICE and other guidelines’ criteria for poor INR 
control and seek to identify novel measures of INR control for optimal risk stratification. 
While the results of this study suggest there is considerable opportunity to 
improve both embolic and bleeding risk, the relationship between poor INR control and 
 27 
these clinical outcomes remains to be determined.  Nevertheless, in accordance with 
NICE guidelines, almost a half of NVAF patients prescribed warfarin for 
thromboembolic risk reduction warrant review to optimise INR control or consider 
alternative anticoagulation strategies where appropriate. 
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Figure legends 
Figure 2. Inclusion criteria for study cohort. 
Figure 2. Number of patients with poor INR control according to NICE criteria.  
Figure 3. Characteristics associated with poor INR control. 
Figure 4.  INR control verses thromboembolic risk 
Supplementary Figure 1. Change in INR control across the study period 
Supplementary Figure 2. Number of patients with TTR<70% or have low or high INRs 
using the NICE low and high criteria. 
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Supplementary Figure 1. Change in INR control across the study period 
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Supplementary Figure 2. Number of patients with TTR<70% or have low or high 
INRs using the NICE low and high criteria. 
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Supplementary table 2. Cohort characteristics and comparisons to patients with INR readings that 
were not available and those with insufficient INR readings for inclusion  
 Cohort analysed INR not available Insufficient INR readingsa 
 N=32380 N=5403 N=10234 
 Mean (SD) Mean (SD), pb Mean (SD), pc 
Age 70.40 (10.61) 70.14 (11.75), 0.098 71.13 (11.89), <0.001 
CHA2DS2Vasc score 3.38 (1.70) 3.70 (1.93), <0.001 3.58 (1.87), <0.001 
 N (%) N (%), pb N (%), pc 
Female 13751 (42.5) 2179 (40.3), 0.003 4302 (42.0), 0.448 
Deprivation index (quintile)    
      1 (most deprived) 5309 (17.5) 927 (17.9), <0.001 1769 (18.5), 0.118 
      2 5875 (19.3) 926 (17.9) 1848 (19.3) 
      3 6728 (22.1) 1056 (20.4) 2142 (22.4) 
      4 5862 (19.3) 819 (15.9) 1778 (18.6) 
      5 (least deprived) 6645 (21.8) 1437 (27.8) 2040 (21.3) 
Excess alcohol intake 850 ( 2.6) 194 ( 3.6), <0.001 346 ( 3.4), <0.001 
Cancer 6134 (18.9) 1677 (31.0), <0.001 2312 (22.6), <0.001 
CKD stage 4+ 375 ( 1.2) 195 ( 3.6), <0.001 263 ( 2.6), <0.001 
Dementia 364 ( 1.1) 346 ( 6.4), <0.001 309 ( 3.0), <0.001 
Diabetes 6876 (21.2) 1417 (26.2), <0.001 2476 (24.2), <0.001 
Epilepsy 206 ( 0.6) 53 ( 1.0), 0.006 88 ( 0.9), 0.021 
Haemorrhagic stroke 204 ( 0.6) 137 ( 2.5), <0.001 72 ( 0.7), 0.461 
Heart failure 7264 (22.4) 1991 (36.8), <0.001 2921 (28.5), <0.001 
Hypertension 21234 (65.6) 3351 (62.0), <0.001 6471 (63.2), <0.001 
Ischaemic heart disease 9641 (29.8) 1892 (35.0), <0.001 3383 (33.1), <0.001 
Ischaemic stroke 6661 (20.6) 1298 (24.0), <0.001 2223 (21.7), 0.013 
Liver disease 611 ( 1.9) 263 ( 4.9), <0.001 299 ( 2.9), <0.001 
Major bleeding event 4536 (14.0) 1533 (28.4), <0.001 1864 (18.2), <0.001 
Peripheral vascular disease 1883 ( 5.8) 481 ( 8.9), <0.001 778 ( 7.6), <0.001 
Respiratory disease 6305 (19.5) 1238 (22.9), <0.001 2308 (22.6), <0.001 
Thromboembolism 426 ( 1.3) 109 ( 2.0), <0.001 180 ( 1.8), 0.001 
Thyroid disease 4079 (12.6) 723 (13.4), 0.114 1344 (13.1), 0.162 
a This group contains patients with a diagnosis of NVAF, prescribed warfarin but with less than 6months 
of INR available for analysis. b P value for comparison between INR not available  group and the cohort 
group analysed. c P value for comparison between INR insufficient group. 
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Supplementary table 3. Comparisons between those with deprivation index data present and missing 
from the final cohort N=32,380 
  Deprivation index present Deprivation index missing 
  N=30419 N=1961 
 Mean (SD) Mean (SD), pa 
Age 70.48 (10.53) 69.05 (11.74),<0.001 
CHA2DS2Vasc score 3.39 (1.69) 3.24 (1.76),<0.001 
 N (%) N (%), pa 
Female 12987 (42.7) 764 (39.0),0.001 
Excess alcohol intake 784 ( 2.6) 66 ( 3.4),0.041 
Cancer 5788 (19.0) 346 (17.6),0.137 
CKD stage 4+ 351 ( 1.2) 24 ( 1.2),0.864 
Dementia 335 ( 1.1) 29 ( 1.5),0.154 
Diabetes 6471 (21.3) 405 (20.7),0.534 
Epilepsy 190 ( 0.6) 16 ( 0.8),0.376 
Haemorrhagic stroke 194 ( 0.6) 10 ( 0.5),0.585 
Heart failure 6818 (22.4) 446 (22.7),0.755 
Hypertension 20029 (65.8) 1205 (61.4),<0.001 
Ischaemic heart disease 9086 (29.9) 555 (28.3),0.148 
Ischaemic stroke 6236 (20.5) 425 (21.7),0.224 
Liver disease 577 ( 1.9) 34 ( 1.7),0.668 
Major bleeding event 4343 (14.3) 193 ( 9.8),<0.001 
Peripheral vascular disease 1789 ( 5.9) 94 ( 4.8),0.052 
Respiratory disease 5938 (19.5) 367 (18.7),0.399 
Thromboembolism 404 ( 1.3) 22 ( 1.1),0.5 
Thyroid disease 3840 (12.6) 239 (12.2),0.597 
a P value for comparison between those with and without deprivation index.  
 
 
 
 
 
  
 37 
 
 
Supplementary table 4. Multivariable regression models of patient characteristics verses INR 
control using BIC and Lasso models. 
 Poor Control Low INRs High INRs TTR <65% 
 BIC Lasso BIC Lasso BIC Lasso BIC Lasso 
Age          
Female         
Excess alcohol         
Major bleeding 
events 
        
Cancer         
CKD stage 4+         
Dementia         
Diabetes         
Epilepsy         
Heart Failure         
Hypertension         
Ischaemic heart 
disease 
        
Ischaemic Stroke         
Liver disease         
PVD         
Respiratory 
disease 
        
Thromboembolism         
Thyroid disease         
Deprivation indexb  
(quintiles) 
 
        
Match between 
BIC and Lasso 
model selectionc  
78.9% 89.5% 89.5% 89.5% 
a All patient characteristics shown in table 1 were modelled, only characteristics that were 
significant in any of models are shown in the table.  
b Deprivation index used is the WIMD quintile.28 
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c  The match between BIC and Lasso model selection was calculated by the sum of variables that 
were selected by both models and not selected by both variables divided by the total number of 
variable in the models. 
 
 
